Preliminary Final Report
Filed with ASX · · 10 pages · English
There were no dividends paid, recommended or declared during the current financial period. Comments The loss for the consolidated entity after providing for income tax amounted to $1,829,261 (31 December 2024: $1,209,373). 3. Net tangible assets 4. Control gained over entities Not applicable. 5. Loss of control over entities Not applicable. 6. Dividends Current period There were no dividends paid,
Nexalis Therapeutics Limited on 6ix
Earlier from Nexalis Therapeutics
- Dec25 Quarterly Activities Report
- Dec25 Appendix 4C Cash Flow Report
- IRX Overview Presentation - SRX-25 and Nexalis
- $12.6m Facility to Drive SRX-25 Development
- Prospectus - Non-Renounceable Rights Issue Offer
Later from Nexalis Therapeutics
- First eligible participant screened - phase 1 IRX-616a study
- First patient dosed in IRX-616a Phase 1 trial
- Significant Milestone - First Patient Screened IRX-211 Ph2
- Mar26 Appendix 4C Cash Flow Report
- Suspension from Quotation
Follow Nexalis Therapeutics into a list and get an email when it puts out news.
Follow Nexalis Therapeutics